| 引用本文: |
汤钰,陈惠媚,陈雄,姚小磊.基于Meta分析和网络药理学探讨五苓散降眼压和治疗黄斑水肿的“异病同治”疗效及机制[J].湖南中医药大学学报,2023,43(3):493-500[点击复制] |
|
| |
|
|
| 本文已被：浏览 1528次 下载 1052次 |
| 基于Meta分析和网络药理学探讨五苓散降眼压和治疗黄斑水肿的“异病同治”疗效及机制 |
| 汤钰,陈惠媚,陈雄,姚小磊 |
| (湖南中医药大学, 湖南 长沙 410208;湖南中医药大学第一附属医院, 湖南 长沙 410007) |
| 摘要: |
| 目的 基于中医学“异病同治”理论，采用Meta分析评价五苓散降眼压和治疗黄斑水肿的效果，并结合网络药理学预测其可能的作用机制。方法 检索知网、万方、维普、PubMmed、Web of science、Embase、Cochrane library等数据库，收集五苓散降眼压和治疗黄斑水肿的随机对照试验（randomized controlled trial, RCT），采用RevMan 5.4软件进行统计处理，评价五苓散降眼压及消黄斑水肿的实际效果。运用中药系统药理学数据库与分析平台（traditional Chinese medicine systems pharmacology database and analysis platform, TCMSP）获取五苓散活性成分及对应靶点，利用GeneCards等数据库检索疾病靶点，将药物与两疾病靶点分别取交集获取共有靶点。通过STRING数据库构建蛋白质-蛋白质相互作用（protein-protein interaction, PPI）网络，使用Cytoscape 3.8.2构建“药物成分-共有靶点-疾病”网络，借助Metascape平台对五苓散降眼压及治疗黄斑水肿的共有靶点进行GO分析和KEGG通路分析。结果 共纳入9篇RCT。Meta分析结果显示五苓散能够有效降低黄斑中心区厚度，并能降低眼压。五苓散同治二病的关键靶点主要涉及CTNNB1、JUN、STAT3、CASP3、CCND1和PPARG。KEGG的富集结果主要集中在AGE-RAGE信号通路、细胞凋亡通路、FoxO信号通路和p53信号通路等。结论 五苓散能够通过多靶点、多通路对黄斑水肿和高眼压相关疾病发挥共同治疗作用，本研究初步揭示了五苓散降眼压和治疗黄斑水肿的潜在机制，结果可为探析中医治疗相关眼病及新药开发提供参考。 |
| 关键词: 五苓散 异病同治 眼压 黄斑水肿 Meta分析 网络药理学 |
| DOI：10.3969/j.issn.1674-070X.2023.03.018 |
| 投稿时间：2022-08-01 |
| 基金项目:国家自然科学基金地区基金项目（81860870）；白求恩·朗沐中青年眼科科研基金（BJ-LM2021009J）；中国博士后科学基金面上资助一等资助项目（2018M640754）；全国中医药创新骨干人才培训项目（湘中医药函〔2019〕67号）；湖南省高层次卫生人才“225”工程培养项目（湘卫函〔2019〕196号）；中医药防治眼耳鼻咽喉疾病湖南省重点实验室开放基金项目（2018YZD02)。 |
|
| Efficacy and mechanism of "same treatment for different diseases" of Wuling Powder in treating ocular hypertension and macular edema based on Meta-analysis and network pharmacology |
| TANG Yu,CHEN Huimei,CHEN Xiong,YAO Xiaolei |
| (Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China) |
| Abstract: |
| Objective To evaluate the efficacy of Wuling Powder (WLP) in lowering intraocular pressure (IOP) and treating macular edema by Meta-analysis, and to predict the possible action mechanism by network pharmacology based on the theory of "same treatment for different diseases" in Chinese medicine. Methods Randomized controlled trials (RCT) of WLP in lowering IOP and treating macular edema were collected by searching CNKI, Wanfang, VIP, PubMed, Web of science, Embase and Cochrane library. Statistical analysis was performed with RevMan 5.4 software, and the actual effects of WLP in lowering IOP and relieving macular edema were evaluated. After that, the active constituents and related targets of WLP were obtained by TCMSP database and targets of the two diseases were obtained by GeneCards database. The common targets were obtained by the drug-disease intersections. The protein-protein interaction (PPI) network was constructed by STRING database and the common targets of drug component-disease network was constructed by Cytoscape 3.8.2. The GO and KEGG pathways analysis of the common targets of WLP in lowering IOP and relieving macular edema was performed with Metascape platform. Results A total of 9 RCTs were included. Meta-analysis results showed that WLP can reduce the thickness of the central macular area and lower IOP. The key targets of WLP in treating the two diseases are CTNNB1, JUN, STAT3, CASP3, CCND1 and PPARG. The result of KEGG enrichment analysis mainly focused on the signaling pathways of AGE-RAGE, apoptosis, FoxO, and p53. Conclusion WLP can play a joint therapeutic effect on macular edema and IOP related diseases through multiple targets and pathways. This study preliminarily reveals the potential mechanism of WLP in treating both macular edema and elevated IOP, which might provide reference for Chinese medicine treatment of related ophthalmopathy and the development of new drugs. |
| Key words: Wuling Powder same treatment for different diseases intraocular pressure macular edema Meta-analysis network pharmacology |
|
二维码（扫一下试试看！） |
|
|
|
|
